Medgenics Inc Preliminary Prospectus Supplement (8637V)

TIDMMEDG TIDMMEDU

RNS Number : 8637V

Medgenics Inc

18 January 2013

 
Press Release  18 January 2013

Medgenics, Inc.

(the "Company")

Preliminary Prospectus Supplement

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that it has filed with U.S. Securities and Exchange Commission ("SEC") a Preliminary Prospectus Supplement, updating the Prospectus dated 26 October, 2012 which forms part of a "shelf" registration statement. The Preliminary Prospectus Supplement can be viewed at the SEC's website at www.sec.gov.

- Ends -

For further information, contact:

 
      Medgenics, Inc.                        Phone: +972 4 902 8900 
       Dr. Andrew L. Pearlman 
       Andrew.pearlman@medgenics.com 
      Abchurch Communications                Phone: +44 207 398 7719 
       Adam Michael 
       Joanne Shears 
       Jamie Hooper 
       jamie.hooper@abchurch-group.com 
      SVS Securities plc (Joint Broker)      Phone: +44 207 638 5600 
       Alex Mattey 
       Ian Callaway 
      Nomura Code Securities (NOMAD/Broker)  Phone: +44 207 776 1219 
       Jonathan Senior 
       Giles Balleny

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCGIGDBXGBBGXI

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024